AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. (original) Tamsulosin hydrochloride, ((R)-5-(2-(2-(2-ethoxyphenoxy)ethylamino)propyl)-2-methoxybenzenesulphona- mide)hydrochloride, in the amorphous form.

2. (original) Tamsulosin hydrochloride in the amorphous form according to claim 1 characterised in that the DSC thermogram thereof exhibits an exothermic peak at about 100° C.

3. (original) Tamsulosin hydrochloride in the amorphous form according to claim 1 characterised in that the IR spectrum thereof exhibits a band at about 3449 cm^{-1}.

4. (original) Tamsulosin hydrochloride in the amorphous form according to claim 3 characterised in that the IR spectrum thereof exhibits the bands substantially as shown in Table 1.

5. (original) Tamsulosin hydrochloride in the amorphous form according to claim 1 characterised in that the X-ray powder diffractogram thereof exhibits the absence of discrete diffractions which are characteristic of crystalline forms.

6. (original) A process for the preparation of the amorphous form of tamsulosin hydrochloride characterised in that it comprises lyophilization of a solution of tamsulosin hydrochloride.

7. (original) The process for the preparation of amorphous tamsulosin hydrochloride according to claim 6 wherein said solution of tamsulosin hydrochloride is aqueous solution.

8. (cancelled)

9. (original) The process for the preparation of amorphous tamsulosin hydrochloride according to claim 8 wherein said solution of tamsulosin hydrochloride is aqueous solution.

10. (original) A pharmaceutical formulation comprising tamsulosin hydrochloride and one or more pharmaceutically acceptable excipients characterised in that it comprises tamsulosin hydrochloride in the amorphous form.

11.-15. (cancelled)